公开(公告)号：US20050261386A1

公开(公告)日：2005-11-24

申请号：US10852365

申请日：2004-05-24

申请人： Bruce Schneider ,  Robert Heller

发明人： Bruce Schneider ,  Robert Heller

IPC分类号： C08J9/00 ,  C08L21/02 ,  C08L75/04

CPC分类号： C08J9/0061 ,  C08G2101/0008 ,  C08G2101/0083 ,  C08J2375/04 ,  C08J2421/00 ,  C08L21/02 ,  C08L75/04 ,  C08L2666/08

摘要： Chemically and thermodynamically amplifying the prior art concept of the heat-producing exothermically-reactive selective polyol and selectable isocyanate chemicals for the conventional production of polyurethane foam-cushioning having a CVR-value fraught with comfort deficiency: The novel amplification herein co-introduces polymerizable latex into the exothermically co-reactable polyol and isocyanate mixture, and which such ancillarily produced exothermic-heat polymerizes the co-introduced latex. The result is economically yielded “latex-enhanced polyurethane foam-cushioning” having a CVR-value not experienced with conventional polyurethane foam-cushioning.

摘要翻译： 化学和热力学放大生产放热反应性选择性多元醇和可选择的异氰酸酯化学品的现有技术概念，用于常规生产具有舒适缺陷的CVR值的聚氨酯泡沫缓冲剂：本文的新型扩增共同引入可聚合胶乳 进入放热共同反应的多元醇和异氰酸酯混合物中，并且这种辅助产生的放热热聚合共引入的胶乳。 经济地获得了具有常规聚氨酯泡沫缓冲的CVR值的“胶乳增强聚氨酯泡沫缓冲”的结果。

公开(公告)号：US5045538A

公开(公告)日：1991-09-03

申请号：US545395

申请日：1990-06-28

申请人： Bruce Schneider ,  Robert A. Greenwald ,  Jonathan Maimon ,  Kenneth Gorray ,  Lorne M. Golub ,  Thomas F. McNamara ,  Nangavarum S. Ramamurthy

发明人： Bruce Schneider ,  Robert A. Greenwald ,  Jonathan Maimon ,  Kenneth Gorray ,  Lorne M. Golub ,  Thomas F. McNamara ,  Nangavarum S. Ramamurthy

IPC分类号： A61K31/65 ,  A61P21/00 ,  A61P43/00

CPC分类号： A61K31/65

摘要： A method for treating mammals suffering from skeletal muscle wasting and/or intracellular protein degradation of skeletal muscle systems by administering to the mammal an amount of tetracycline which results in a significant reduction of the muscle wasting and protein degradation is disclosed. In addition, there is also disclosed a method of increasing the protein content of skeletal muscle systems of mammals by administration of tetracyclines. The tetracyclines useful in the above methods are both antimicrobial and non-antimicrobial. In a preferred embodiment, the method of treatment utilizes a non-antimicrobial tetracycline such as dedimethylaminotetracycline (CMT).